Envision Pharma
Envision Pharma Group, commonly referred to as Envision Pharma, is a leading provider of innovative solutions in the life sciences industry, headquartered in Great Britain. Founded in 2001, the company has established a strong presence in key operational regions, including North America and Europe, focusing on medical communications, technology, and data analytics. Envision Pharma is renowned for its unique offerings, such as advanced software platforms and strategic consultancy services that enhance the efficiency of pharmaceutical and biotechnology companies. With a commitment to excellence, the company has achieved significant milestones, positioning itself as a trusted partner in the industry. Its dedication to delivering high-quality, evidence-based solutions has earned Envision Pharma a notable reputation, making it a preferred choice for clients seeking to navigate the complexities of the healthcare landscape.
DitchCarbon Score
How does Envision Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Envision Pharma's score of 42 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Envision Pharma's reported carbon emissions
In 2023, Envision Pharma Group Ltd reported total carbon emissions of approximately 14,645,000 kg CO2e. This figure includes 13,000 kg CO2e from Scope 1 emissions, 291,000 kg CO2e from Scope 2 emissions, and a significant 14,341,000 kg CO2e from Scope 3 emissions, primarily driven by business travel and purchased goods and services. The company has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 55% by 2030, using 2022 as the baseline year. Additionally, Envision Pharma is targeting a 52% reduction in Scope 3 emissions from business travel per full-time equivalent (FTE) by 2030, with a focus on ensuring that 75% of its suppliers have science-based targets by 2028. These initiatives align with industry standards for climate action, demonstrating Envision Pharma's commitment to sustainability and reducing its overall carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 40,000 | 0,000,000,000 | 00,000 | 000,000 | 00,000 |
| Scope 2 | 608,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 1,689,000 | 000,000 | 00,000 | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Envision Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
